Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer

Gynecologic Oncology

Volumn 138, Issue 1, 2015, Pages 70-77

  Janco, Jo Marie Tran ^a   Glaser, Gretchen ^b   Kim, Bohyun ^a   McGree, Michaela E ^a   Weaver, Amy L ^a   Cliby, William A ^a   Dowdy, Sean C ^a   Bakkum Gamez, Jamie N ^a  

^a MAYO CLINIC   (United States)

^b CARILION CLINIC   (United States)

Author keywords

Cytoreduction; Ovarian cancer; Preoperative prediction

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMEN; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; BODY MASS; BOOTSTRAPPING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE PERITONEAL THICKENING; FEMALE; HUMAN; LIVER; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONCOLOGIST; OVARY CARCINOMA; PATIENT SELECTION; PELVIS; PERITONEAL DISEASE; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SPLEEN; STEP WISE MULTIPLE REGRESSION; TUMOR VOLUME; AGE; BIOLOGICAL MODEL; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PATHOLOGY; STATISTICAL MODEL;

AGE FACTORS; AGED; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84931573506     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.04.013     Document Type: Article

References (37)

1. N. Howlader, A.N. Noone, M. Krapcho, J. Garshell, D. Miller, S.F. Altekruse, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, and K.A. Cronin SEER Cancer Statistics Review, 1975-2011 2014 National Cancer Institute (www.seer.cancer.gov)
2. T.C. Randall, and S.C. Rubin Cytoreductive surgery for ovarian cancer Surg. Clin. N. Am. 81 2001 871 883
3. WJ Hoskins Epithelial ovarian carcinoma: principles of primary surgery Gynecol. Oncol. 55 1994 S91 S96
4. G.D. Aletti, S.C. Dowdy, B.S. Gostout, M.B. Jones, C.R. Stanhope, T.O. Wilson, K.C. Podratz, and W.A. Cliby Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Obstet. Gynecol. 107 2006 77 85
5. A. Elattar, A. Bryant, B.A. Winter-Roach, M. Hatem, and R. Naik Optimal primary surgical treatment for advanced epithelial ovarian cancer Cochrane Database Syst. Rev. 8 2011 CD007565
6. N.S. Horowitz, A. Miller, B. Rungruang, S.D. Richard, N. Rodriguez, M.A. Bookman, C.A. Hamilton, T.C. Krivak, and G.L. Maxwell Does aggressive surgery improve outcomes? interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 J. Clin. Oncol 33 2015 937 943
7. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, R.S. Mannel, K. DeGeest, E.M. Hartenbach, R. Baergen, and Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
8. I.T. Vergote, G. Claes, Frederic Amant, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, Rene H.M. Verheijen, Maria E.L. van der Burg, Angel J. Lacave, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, Cesar Mendiola, Corneel Coens, Leen Verleye, Gavin C.E. Stuart, Sergio Pecorelli, Nick S. Reed, R. Angioli, J. Bentley, P. Berteloot, P. Bessette, K. Boman, M. Buist, K. Chan, S. Chan, P. Coronado Martin, R. Counsell, D.J. Cruickshank, J. Davis, J. De Greve, C.F. De Oliveira, B. De Valk, C. Dittrich, L. Elit, G. Favalli, A. Floquet, P. Gauthier, E. Gerdin, P. Ghatage, E. Gilby, N. Gleeson, W. Gotlieb, J.A. Green, R. Grimshaw, M. Heywood, V. Hirsch, K. Hoekman, A. Honkoop, P. Hoskins, P. Kannisto, J. Kaern, D. Katsaros, K. Kieser, T.V. Kristeller, E. Leblanc, J. Ledermann, K. Leunen, R. Lotocki, T. Maggino, C. Marth, L. Martin, L. Massuger, D. Miller, B. Mosgaard, F. Mota, P. Neven, M. Nooij, R. Nordal, A. Nordin, P.B. Ottevanger, A. Papadopoulos, E. Petru, M. Plante, C. Popadiuk, D. Provencher, C. Redman, K.J. Roozendaal, G. Rustin, A.H. Sadozye, R. Sandvei, J.M. Seoane, M.I. Sereni, B. Sert, N. Siddiqui, P. Speiser, B. Tholander, G. Tognon, B. Trimbos, M. Trudeau, M. Van Baal, H.C. Van Doorn, J. Van Der Velden, K. Van Eygen, J.B. Vermorken, J.A. Vidart Aragon, C.W.M. Wensveen, P. Zola, A. Anastosopoulou, U. Bethe, K. Dehaes, A. Demeester, G. Demonty, E. De Heusch, M. De Rouck, L. Giurgea, G. Hoctin-Boes, I. Hoctin-Boes, G. Teodorovic, K. Ven, I. Van Luijk, M. Bacon, and E. Eisenhauer Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N. Engl. J. Med. 363 2010 943 953
9. J.D. Wright, C.V. Ananth, J. Tsui, S.A. Glied, W.M. Burke, Y.S. Lu, A.I. Neugut, T.J. Herzog, and D.L. Hershman Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer 120 2014 246 1254
10. S. Kang, and S.Y. Park To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer Ann. Oncol. s8 2011 viii23 viii28
11. A.E. Axtell, L.M., R.E. Bristow, S.C. Dowdy, W.A. Cliby, S. Raman, J.P. Weaver, M. Gabbay, M. Ngo, S. Lentz, I. Cass, A.J. Li, B.Y. Karlan, and C.H. Holschneider Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer J. Clin. Oncol. 25 2007 384 389
12. U. Metser, C. Jones, L.M. Jacks, M.Q. Bernardini, and S. Ferguson Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography: correlation with surgery and surgical outcome Int. J. Gynecol. Cancer 21 2011 1391 1398
13. S.H. Chandrashekhara, S. Thulkar, D.N. Srivastava, L. Kumar, R. Hariprasad, S. Kumar, and M.C. Sharma Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer Br. J. Radiol. 84 2011 38 43
14. G. Glaser, M. Torres, B. Kim, G. Aletti, A. Weaver, A. Mariani, L. Hartmann, and W.A. Cliby The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer Gynecol. Oncol. 130 2013 280 283
15. S.K. Allensworth, C.L. Langstraat, J.R. Martin, M.A. Lemens, M.E. Mcgree, A.L. Weaver, S.C. Dowdy, K.C. Podratz, and J.N. Bakkum-Gamez Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer Gynecol. Oncol. 130 2013 499 504
16. N.S. Horowitz, A. Miller, B.J. Rungruang, T.C. Krivak, S.D. Richard, C.A. Hamilton, N. Rodriguez, M.A. Bookman, and G.L. Maxwell Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis Abstract - Society of Gynecologic Oncology Annual Meeting, March 2014 2014
17. S.L. Tucker, G.K., S.M. Herbrich, A.K. Unruh, A.M. Nick, E.K. Crane, R.L. Coleman, J. Guenthoer, H.J. Dalton, S.Y. Wu, R. Rupaimoole, G. Lopez-Berestein, B. Ozpolat, C. Ivan, W. Hu, K.A. Baggerly, and A.K. Sood Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer Clin. Cancer Res. 20 2014 3280 3288
18. S.C. Dowdy, S.A. Mullany, K.R. Brandt, B.J. Huppert, and W.A. Cliby The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 101 2004 346 352
19. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am. J. Obstet. Gynecol. 197 676 2007 e671 e677
20. Development Core Team R: A Language and Environment for Statistical Computing 2014 R Foundation for Statistical Computing Vienna, Austria (URL http://www.R-project.org/)
21. F.E. Harrell, K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat. Med. 15 1996 361 387
22. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J. Clin. Oncol. 20 2002 1248 1259
23. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 47 1992 149 156
24. S.J. Chang, M. Hodeib, J. Chang, and R.E. Bristow Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol. Oncol. 130 2013 493 498
25. D.S. Chi, E.L. Eisenhauer, J. Lang, J. Huh, L. Haddad, N.R. Abu-Rustum, D.A.L.Y. Sonoda, M. Hensley, and R.R. Barakat What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 103 2006 559 564
26. I.T. Vergote, C.G. Trope, F. Amant, G.B. Kristensen, T. Ehlen, N. Johnson, R.H. Verheijen, M.E. van der Burg, A.J. Lacave, P.B. Panici, G.G. Kenter, A. Casado, C. Mendiola, C. Coens, L. Verleye, G.C. Stuart, S. Pecorelli, N.S. Reed, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group, and NCIC Clinical Trials Group Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N. Engl. J. Med. 363 2010 943 953
27. S. Kehoe, J. Hook, M. Nankivell, G.C. Jayson, H.C. Kitchener, T. Lopes, D. Luesley, T. Perren, S. Bannoo, M. Mascarenhas, S. Dobbs, S. Essapen, J. Twigg, J. Herod, W.G. McGluggage, M. Parmar, and A.M. Swart Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial J. Clin. Oncol. 31 2013 ((suppl): abst 5500)
28. R.E. Bristow, E.L. Eisenhauer, A. Santillan, and D.S. Chi Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol. Oncol. 104 2007 480 490
29. A. Fagotti, G. Ferrandina, F. Fanfani, G. Garganese, G. Vizzielli, V. Carone, M.G. Salerno, and G. Scambia Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma Am. J. Obstet. Gynecol. 199 6 Dec 2008 e1 e6 10.1016/j.ajog.2008.06.052 (642.e1-6, Epub 2008 Sep 17)
30. J.L. Brun, R. Rouzier, S. Uzan, and E. Daraï External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score Gynecol. Oncol. 110 2008 354 359
31. E. Chereau, L.V., M. Ballester, C. Coutant, F. Selle, A. Cortez, E. Daraï, J. Leveque, and R. Rouzier External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery Anticancer Res. 31 2011 4469 4474
32. E. Chereau, L.V., M. Ballester, C. Coutant, F. Selle, A. Cortez, E. Daraï, J. Leveque, and R. Rouzier Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer Am. J. Obstet. Gynecol. 202 2010 (178.e171-e110)
33. C. Fotopolou, R.R., E.I. Braicu, S.C. Schmidt, W. Lichtenegger, and J. Sehouli Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients EJSO 36 2010 1202 1210
34. O. Gemer, M. Gdalevich, M. Ravid, B. Piura, A. Rabinovich, T. Gasper, A. Khasper, M. Voldarsky, L. Linov, I.B. Shachar, E.Y. Anteby, and O. Lavie A multicenter validation of computerized tomography models as predictors of non-optimal primary cytoreduction of advanced epithelial ovarian cancer EJSO 35 2009 1109 1112
35. E.M.J. Eijkemans, D. de Jong, S.L. Fong, C.G. Gerestein, G.S. Kooi, A. Baalbergen, M.E.L. van der Burg, C.W. Burger, and A.C. Ansink Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma Oncology 72 2007 293 301
36. R.S. Suidan, P.T. Ramirez, D.M. Sarasohn, J.B. Teitcher, S. Mironov, R.B. Iyer, Q. Zhou, A. Iasonos, H. Paul, M. Hosaka, C.A. Aghajanian, M.M. Leitao Jr., G.J. Gardner, N.R. Abu-Rustum, Y. Sonoda, D.A. Levine, H. Hricak, and D.S. Chi A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer Gynecol. Oncol. 134 2014 455 461
37. K.M. Nieman, H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, M.R. Zillhardt, I.L. Romero, M.S. Carey, G.B. Mills, G.S. Hotamisligil, S.D. Yamada, M.E. Peter, K. Gwin, and E. Lengyel Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat. Med. 17 2011 1498 1503